All Doctors have to Re-Register with NMC: Here are 6 Points for the National Medical Register

New Delhi: All doctors practising modern medicine including MBBS, MD, MS, Super specialists will have to re-register themselves with the National Medical Commission (NMC) as the Apex Medical Body has now launched the much-awaited National Medical Register (NMR) portal.

The launch was done by the Union Minister for Health & Family Welfare, Shri Jagat Prakash Nadda, in the presence of the Union Minister of State (MoS) for Health & Family Welfare, Smt. Anupriya Patel and virtual presence of the Union MoS for Health & Family Welfare, Shri Prataprao Jadhav.

NMR is mandated under Section 31 of the NMC Act, 2019 which states that the Ethics & Medical Registration Board (EMRB) of NMC shall maintain a National Register in electronic form containing the name, address, and all recognized qualifications possessed by a licensed medical practitioner. 

Here are the 6 key points related to NMR that the doctors should know:

(1) What is the National Medical Register (NMR)? 

NMR will be a comprehensive dynamic database for all allopathic registered doctors in India. The uniqueness of the NMR is that it is linked with the Aadhaar ID of the doctors which ensures the individual’s authenticity.

(2) Mandatory Registration on NMR? 

All the MBBS doctors, who are already registered on the Indian Medical Register (IMR), have to mandatorily register again on the NMR portal of NMC, the recent release by the Government has stated.

(3) How to Register on NMR? 

In order to start the registration process, the doctors need to keep ready these following documents ready-

(a) a digital copy of the Degree (MBBS) Certificate,

(b) the Registration Certificate of the State Medical Council/Medical Council of India, where the doctor got their first time registration. 

(c) Aadhaar number is also required to commence the registration process.

The link for the registration in the NMR is https://nmr-nmc.abdm.gov.in/nmr/v3/

(4) Registration of Additional Data on NMR: 

Doctors can register additional data on the NMR portal through these following steps:

♦ Additional details like registration and qualification credentials can be manually entered and submitted through the NMR portal.

♦ Following this, the application is automatically forwarded to the respective State Medical Council for verification.

♦ Consequently, the SMC would forward the application to the relevant college or institute for further view. 

♦ After successful verification by the State Medical Council, the application will be sent to the National Medical Commission (NMC) for verification. 

♦ After the completion of the NMC verification, a unique NMR ID will be issued. 

♦ During this process, doctors can opt to join the Healthcare Provider Registry which will link them to the broader digital healthcare ecosystem.

(5) Features of the NMR Portal: 

Using the NMR portal of the Apex Medical Commission, all the stakeholders, including the SMCs and educational institutions can log in and verify applications from a single platform.

The NMR portal offers a variety of features, including the ability to add additional qualifications, track applications, suspend licenses, and issue NMR ID cards and digital doctor certificates.

The National Health Authority (NHA)  will further provide support for the development of the NMR, including the future release of an enhanced version of the portal. This will include direct integration with the next software, continuing medical education, and credit points.

(6) Accessibility of NMR Data (What Doctor Data will be Public and What will be Private):

All the medical colleges/institutions (including the Institutes of National Importance (INIs) etc.) SMCs are interlinked on the newly launched NMR portal.

While the public release has not specified that what data will be accessible to the Public and which will remain private, it stated that only some of the data will be visible to the Public.

Others will only be visible to the Ethics & Medical Registration Board (EMRB) in the National Medical Commission (NMC), State Medical Councils (SMCs), the National Board of Examinations (NBE) and Medical Institutions (including INIs, etc.) and Registered Medical Practitioners (RMPs) as per the requirements.

Speaking at the event, Shri Nadda commended the NMC and National Health Authority (NHA) “for their hard work and coming out with the National Health Register which will be a comprehensive and dynamic database for all allopathic (MBBS) registered doctors in India.” He stated that “the Prime Minister’s vision is to make India digitally sound and that can happen if the health ecosystem is also digitally sturdy. The National Health Register is a much-awaited step in this direction that will strengthen the digital healthcare ecosystem and will ensure quality healthcare to the people of India”. He further added that the National Medical Register will be upgraded and augmented with continuous improvements in the registration process on the portal.

Highlighting the role of the State Medical Councils (SMCs), Shri Nadda stated that “the State Medical Councils are major stakeholders in the development and maintaining of National Medical Register and facilitating the registration process.” He urged the SMCs “for their active participation and to fasten the registration process” as their “efforts of authentication and speed of authentication will be a key factor in the success of NMR”. He further added that “we are also moving in the direction of launching a similar register for the paramedics and other healthcare professionals.”

Terming the launch of the NMR “a momentous occasion” Smt. Anupriya Patel, Union MoS Health & Family Welfare, stated that “the need for the National Medical Register has been felt for very long. The NMR is important as authentic data on doctors across the country is crucial. The data on doctors to date has been in a scattered form that needs revision, and updation, and the NMR portal will ensure that. The easy registration process will ensure the maintenance of authentic data. This authenticity of information holds a lot of value because India wants to create a huge digital health ecosystem and creating the digital registry of doctors will be an important pillar for that.”

Highlighting the importance of the NMR, Shri Prataprao Jadhav, Union MoS Health & Family Welfare stated that the NMR portal will ensure dynamic, authentic, and consolidated data on the doctors in the country. The speedy and easy registration process on the portal will facilitate the timely updation of the data. This will lead to transparency and quality of the medical professionals and will ensure the trust of the people in the healthcare system, as they will get verified information in a transparent manner. The government is working under the vision of the Prime Minister of “Reform, Perform, and Transform”, and the launch of NMR is a step in the direction of fulfilling the government’s commitment to providing quality healthcare to the people”.

Speaking at the event, Union Health Secretary Shri Apurva Chandra stated that “Till date, there was lack of comprehensive data that could provide a detailed and holistic picture of aspects like total numbers of doctors in the country, those that have left the country, those who have lost their license to practice, or the numbers and details of doctors that have lost their lives. The launch of the NMR will ensure the provision of data of its more than 13 lakh doctors”. Shri Chandra further stated that “the NMR will be a part of the Healthcare Professional Registry under the Ayushman Bharat Digital Mission and will contain all the details of the medical professionals.”

Dr. B.N. Gangadhar, Chairman, National Medical Commission, Smt. L.S. Changsan, Additional Secretary and CEO (NHA), Dr. B. Srinivas, DDG (ME) & Secretary, Medical Commission, Smt. V. Hekali Zhimomi, Additional Secretary, MoHFW, Shri Pushpendra Rajput, Joint Secretary, MoHFW, Shri Kiran Gopal Vaska, Joint Secretary, ID & MD (ABDM), National Health Authority, Dr. Vijay Oza, President, PMEB, National Medical Commission, Dr. B. Srinivas, DDG (ME) & Secretary, National Medical Commission, Dr. Vijaya Lakshmi Nag, Member, EMRB, National Medical Commission, and other senior officials from the Ministry were also present at the event. The event was also joined virtually by the representatives of State Medical Councils.

Powered by WPeMatico

MCC NEET 2024 Round 1 Counselling Provisional Results Announced

New Delhi- The Medical Counselling Committee (MCC) has released the provisional result of the National Eligibility and Entrance Test-Undergraduate (NEET UG) Round 1 Counselling 2024.

As per the result, a total of 26109 students have been declared qualified for NEET UG Round 1 Counselling 2024. The provisional result has been declared on the official website of MCC, therefore candidates can download and view the provisional result on the website. Therefore, in case of any discrepancy found in the provisional result, candidates are instructed to immediately inform the MCC of DGHS through email on the email ID by 01:00 PM today i.e. 24 August 2024, after which the provisional result will be treated as ‘Final’.

The Candidates are further informed through the notice in this regard, that the provisional result is only indicative in nature and subject to change. The candidates cannot claim any right over the allotted seat in the provisional result and the provisional result cannot be challenged before the Court of Law. Therefore, the Candidates are advised to approach the allotted college/institute only after the declaration of the Final Result and only after downloading the allotment letter from the MCC website.

Also Read: MCC NEET 2024 Counselling Registrations Begin, Apply now

NEET UG Round 1 counselling 2024 began on August 14, 2024, and will continue till September 6 to 7, 2024. Below is the detailed schedule-

SCHEDULE

S.NO

SCHEDULE FOR ADMISSION

ALL INDIA QUOTA/DEEMED & CENTRAL UNIVERSITIES

SHARING OF JOINED CANDIDATE’S DATA BY MCC

STATE COUNSELLING

SHARING OF JOINED CANDIDATE’S DATA BY STATES

1

Ist Round of Counselling.

14th August, 2024 to 23rd August Aug, 2024

30th Aug to 31st Aug, 2024

21st Aug to 29th Aug, 2024

6th to 7th Sept., 2024

2

Last date of Joining.

The last date of Joining is 17th July 2024.

–

25th July, 2024.

–

3

2nd round of Counselling.

5th Sept., 2024 to 13th Sept., 2024

21st Sept. To 22nd Sept. 2024

11th Sept., 2024 to 20th Sept., 2024

27th Sept to 28th Sept., 2024

4

Last date of joining.

20th Sept, 2024

–

26th Sept, 2024

–

5

Round-3.

26th Sept., 2024 to 5th Oct., 2024

13th Oct., to 15th Oct., 2024

3rd Oct., 2024 to 12th Oct., 2024

19th Oct., 2024

6

Last date of joining.

12th Oct., 2024

–

18th Oct., 2024

–

7

Stray Vacancy.

16th Oct., 2024 to 23rd Oct., 2024

–

21st Oct., 2024 to 25th Oct., 2024

–

Last date of joining.

30th Oct., 2024

–

30th Oct., 2024

–

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/notice-ug-2024-249300.pdf
https://medicaldialogues.in/pdf_upload/reuslt-249301.pdf

Powered by WPeMatico

Zydus Lifesciences to buy 50 percent stake in Sterling Biotech from Perfect Day

Ahmedabad: Zydus Lifesciences Limited through its wholly owned subsidiary, and Perfect Day Inc., a
Temasek portfolio company have signed an agreement wherein Perfect Day will sell
its ~50% shareholding in Sterling Biotech Limited.

Post this transaction, Sterling Biotech will
become a 50:50 Joint Venture (“JV”) with equal representation on the Board.
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free
protein to cater to the global markets. The JV will accelerate the production of high-quality and ecofriendly protein products, reduce environmental impact, and cater to the growing consumer demand for
fermentation-based and ethically sourced nutrition.

As per the release, the acquisition will mark Zydus’ foray into specialised biotech products for health and nutrition,
specifically catering to consumers who prefer animal-free protein or suffer from lactose intolerance.

Perfect Day’s precision-fermented protein is found in ice creams, cream cheese, sports nutrition
products, and baked goods with high functionality benefits and lower environmental impact.

“This transaction between Perfect Day and Zydus underlines the importance of the emerging global
markets for environmentally friendly and sustainable products. Perfect Day will significantly enhance
its technological capabilities in India as part of its emerging market growth strategy, while Zydus will
continue to leverage its strong manufacturing and commercial expertise. Through this manufacturing
partnership both the parties reaffirm their commitment of making India a bright spot in global supply
chain,” the release stated.


SBL is currently engaged in manufacturing and selling of fermentation-based API products and gelatine.
With a clear vision of focussing on animal-free protein products the JV partners will also take a strategic
view on API and gelatine business.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said
“We are dedicated to promoting growth through partnerships and are consistently exploring new
collaborations to position India as a premier global supply chain hub. We are excited to join forces with
Perfect Day and create a win-win combination that leverages both our strengths and expertise to create
value for the consumers.”
Mr. Narayan TM, Interim CEO, Perfect Day said, “This partnership allows Perfect Day to significantly
boost its capabilities to meet the demands of the fast-growing global market. We deeply value our
collaboration with Zydus and believe this joint venture will allow both parties to benefit from each
other’s expertise.”
NovaaOne Capital Private Limited is acting as an exclusive financial advisor to Perfect Day for this
transaction.

Read also: Zydus Lifscience Gets CDSCO Panel Nod to Study Measles and Rubella Vaccine

Powered by WPeMatico

Routine Protamine Use Enhances Hemostasis and Reduces Vascular Complications After TAVI: ACE-PROTAVI Trial

Australia: The routine use of protamine enhances hemostasis following transfemoral transcatheter aortic valve implantation (TAVI) procedures, findings from ACE-PROTAVI randomized clinical trial have shown. The study, published in the journal JAMA Cardiology elucidates the promising
results of protamine administration after transfemoral TAVI by promoting
hemostasis and decreased time to hemostasis (TTH).

“In the ACE-PROTAVI randomized clinical trial, involving 410 patients across three Australian hospitals, routine administration of protamine after TAVI resulted in a higher rate of successful hemostasis and a reduced risk of vascular complications compared to placebo,” the researchers reported. 

Transfemoral transcatheter aortic valve implantation is a minimally invasive procedure used to replace a damaged or diseased
aortic valve in the heart. Vascular complications following transfemoral TAVI continue to be a significant source of procedure-related complications. Routine
use of protamine to reverse anticoagulation at the end of transfemoral TAVI may
help decrease these complications, although there is limited data available.

To evaluate the efficacy and safety of routine protamine administration
after transfemoral TAVI, scientists conducted an ACE-PROTAV randomized clinical
trial.

For this trial, Pieter A. Vriesendorp, Heart Centre, The Alfred Hospital,
Melbourne, Australia, and the team recruited 410 patients from 3
Australian hospitals between December 2021 and June 2023 with a 1-year
follow-up period.

All patients accepted for transfemoral TAVI by a
multidisciplinary heart team were eligible for enrollment. Eligible
patients were randomized 1:1 between routine protamine administration and
placebo. Out of 410 patients, 199 patients were in the protamine group
and 211 in the placebo group. Measurements were done using odds
ratios(ORs)

The study results reveal:

  • The
    median (IQR) patient age in the protamine group was 82 (77-85) years, and 68 of
    199 patients receiving protamine (34.2%) were female.
  • The
    median (IQR) patient age in the placebo group was 80 (75-85) years, and 89 of
    211 patients receiving the placebo (42.2%) were female.
  • Patients who received protamine
    administration at the start of the procedure experienced a higher rate of
    successful hemostasis (97.9% in 188 of 192 patients) compared to those who
    received a placebo (91.6% in 186 of 203 patients), with an absolute risk
    difference of 6.3%
  • The median time to hemostasis (TTH) was
    shorter for those given protamine upfront, with a median of 181 seconds (IQR
    120-420) compared to 279 seconds (IQR 122-600) for the placebo group.
  • Routine administration of protamine led to
    a lower risk of the composite outcome in the protamine group (5.2% in 10 of 192
    patients) compared to the placebo group (12.8% in 26 of 203 patients), with an
    odds ratio of 0.37.
  • This reduction was mainly due to a lower
    rate of minor vascular complications in the protamine group. Additionally, no
    adverse events were linked to the use of protamine.

“The advantages of
protamine were evident in decreased minor vascular complications, shorter
procedural time, and reduced post-procedural hospital stay for patients who
received routine protamine compared to those who received a placebo,”
researchers concluded.

Reference: Vriesendorp PA, Nanayakkara S, Heuts S, et al. Routine Protamine Administration
for Bleeding in Transcatheter Aortic Valve Implantation: The ACE-PROTAVI
Randomized Clinical Trial. JAMA Cardiol. Published online August 14, 2024.
doi:10.1001/jamacardio.2024.2454

Powered by WPeMatico

FDA approves season’s updated mRNA COVID vaccines for protection against current variants

The U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX Inc. and Pfizer Inc.

In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines. Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.

“Vaccination continues to be the cornerstone of COVID-19 prevention,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “These updated vaccines meet the agency’s rigorous, scientific standards for safety, effectiveness, and manufacturing quality. Given waning immunity of the population from previous exposure to the virus and from prior vaccination, we strongly encourage those who are eligible to consider receiving an updated COVID-19 vaccine to provide better protection against currently circulating variants.”

The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, both of which are authorized for emergency use for individuals 6 months through 11 years of age.

What You Need to Know

  • Unvaccinated individuals 6 months through 4 years of age are eligible to receive three doses of the updated, authorized Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated, authorized Moderna COVID-19 Vaccine.
  • Individuals 6 months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines (timing and number of doses to administer depends on the previous COVID-19 vaccine received).
  • Individuals 5 years through 11 years of age regardless of previous vaccination are eligible to receive a single dose of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines; if previously vaccinated, the dose is administered at least 2 months after the last dose of any COVID-19 vaccine.
  • Individuals 12 years of age and older are eligible to receive a single dose of the updated, approved Comirnaty or the updated, approved Spikevax; if previously vaccinated, the dose is administered at least 2 months since the last dose of any COVID-19 vaccine.
  • Additional doses are authorized for certain immunocompromised individuals ages 6 months through 11 years of age as described in the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine fact sheets.

Individuals who receive an updated mRNA COVID-19 vaccine may experience similar side effects as those reported by individuals who previously received mRNA COVID-19 vaccines and as described in the respective prescribing information or fact sheets. The updated vaccines are expected to provide protection against COVID-19 caused by the currently circulating variants. Barring the emergence of a markedly more infectious variant of SARS-CoV-2, the FDA anticipates that the composition of COVID-19 vaccines will need to be assessed annually, as occurs for seasonal influenza vaccines.

For today’s approvals and authorizations of the mRNA COVID-19 vaccines, the FDA assessed manufacturing and nonclinical data to support the change to include the 2024-2025 formula in the mRNA COVID-19 vaccines. The updated mRNA vaccines are manufactured using a similar process as previous formulas of these vaccines. The mRNA COVID-19 vaccines have been administered to hundreds of millions of people in the U.S., and the benefits of these vaccines continue to outweigh their risks.

On an ongoing basis, the FDA will review any additional COVID-19 vaccine applications submitted to the agency and take appropriate regulatory action.

The approval of Comirnaty (COVID-19 Vaccine, mRNA) (2024-2025 Formula) was granted to BioNTech Manufacturing GmbH. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) was issued to Pfizer Inc.

The approval of Spikevax (COVID-19 Vaccine, mRNA) (2024-2025 Formula) was granted to ModernaTX Inc. and the EUA amendment for the Moderna COVID-19 Vaccine (2024-2025 Formula) was issued to ModernaTX Inc.

Powered by WPeMatico

CENTAC Invites Applications From UT Candidates for BHMS, BUMS, BSMS 2024 Admissions, details

Puducherry- Centralised Admission Committee (CENTAC) is inviting online applications from the Union Territory of Puducherry candidates for admission into undergraduate BSMS, BUMS and BSMS Medical Degree Courses. Candidates from the Union Territory of Puducherry will be granted admission to sponsored seats in other states for the academic year 2024-25.

As per the notice issued in this regard, it has been directed that the candidates have to submit a self-attested copy of the application to the Secretary of the Selection Committee of the Directorate of Indian Medicine and Homeopathy, Arignar Anna Government Hospital of Indian Medicine Campus by 5.30 pm on August 27 in advance.

Also Read: CENTAC Invites Applications For NEET MDS Round 3 Counselling for NRI, Management Quota Vacancies, details

Also, another self-attested copy of the application must be submitted to the Coordinator of CENTAC, Kamarajar Manimandapama Campus before 30th August 2024, 5.00 PM.

Meanwhile, the eligibility for admission to BSMS, BUMS and BHMS degree courses for this academic year will be entirely based on the marks obtained in the National Eligibility and Entrance Test-Undergraduate (NEET UG) 2024 conducted by the National Testing Agency (NTA).

CENTAC is a common admission portal for all the colleges of Puducherry and is established by the Government of Puducherry. Under this, the candidates who have passed the qualifying examination and appeared in such a qualifying examination are eligible for admission. There are various courses under its umbrella. Centralised Admission Committee (CENTAC), Government of Puducherry, conduct admissions for first-year MBBS, BAMS, BDS, BVSc & AH, BPT, BSc (Nursing), BSc (MLT), BPharma, BA LLB, LLB, BSc (Agriculture) and BSc (Horticulture) programmes and postgraduate programmes. To confirm admission, candidates must attend the counselling in person at a specified date and time. After CENTAC 2024 counselling, the authorities will allot seats to the candidates.

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/centac-invites-applications-from-ut-candidates-for-bsms-bums-bhms-medical-2024-admission-249166.pdf

Powered by WPeMatico

SCB Medical College Rape Case: Dean asked to rusticate senior resident doctor

Bhubaneswar: Days after the arrest of a senior resident doctor at SCB Medical College and Hospital (MCH), for allegedly raping two woman patients during their echocardiogram tests, the Odisha Director of Medical Education and Training (DMET) has directed the hospital’s dean and principal to rusticate him. 

The Odisha government on Thursday directed the authorities of SCB Medical College Hospital (SCBMCH) in Cuttack to rusticate a senior resident doctor, accused of raping two women patients.

This decision follows a recommendation from the Director of Medical Education and Training (DMET), Santosh Kumar Mishra, who led an inquiry into the allegations.

In a letter to the SCB Medical College principal, Mishra instructed that the accused doctor be rusticated. “The principal of the SCB Medical College Hospital will rusticate the accused doctor,” Mishra told PTI.

Also Read:Cardiologist arrested for allegedly sexually assaulting two patients at SCB Medical College Hospital

According to the PTI report, a three-member committee confirmed the doctor’s involvement in the offences and found no evidence of conspiracy or false implication, according to the DMET.

Medical Dialogues team had earlier reported that in a shocking incident, a 37-year-old cardiologist was arrested for allegedly raping two women patients at SCB Medical College and Hospital in Cuttack.

The officer told media persons that both the women came out of the room after the test and told the complainant that they were sexually abused by the doctor during testing. 

The doctor, a resident of Bhopal, Madhya Pradesh, was arrested on August 13 following a complaint by the two women at Mangalabag police station in Cuttack. The doctor’s wife has claimed that her husband was framed.

The alleged rapes took place on August 11 when the patients came in for an echocardiogram (ECHO) test.

The Health & Family Welfare Department of the state government took the incident seriously and formed a probe committee consisting of Dr Santosh Kumar Mishra (DMET), Dr Sudhansu Sekhar Mishra (Superintendent, SCB MCH, Cuttack), Dr Roma Rattan (Joint DMET), and the I/c Dean & Principal of SCB Medical College.

Also Read:SCB Medical College Hospital House Surgeons, Nursing Staff conflict resolved after discussion with CMC Commisioner

Powered by WPeMatico

Late Morning Meals Linked to Lower Type 2 Diabetes Risk in certain ethnic groups, claims study

Researchers in a recently conducted study reported that risk for developing type 2 diabetes is reduced with meals consumed in the late morning among Hispanic/Latino adults in the US. The Hispanic Community Health Study/Study of Latinos has provided substantial insights into the implications of meal timing toward the risk of diabetes. Their findings propose that eating more during late morning hours can be a new approach to prevent diabetes. This was published in Diabetes Care by Jin Dai and colleagues. The HCHS/SOL is a multicenter, community-based, prospective cohort study.

The current analysis included 8,868 Hispanic/Latino adults free of diabetes at baseline. Energy intake and baseline meal timing GL were assessed for each meal timing at baseline through two 24-hour dietary recalls by investigators. Incident diabetes cases were identified from annual follow-up calls and visit 2 examinations. Hazard ratios for incident diabetes were estimated with Cox proportional hazards models accounting for the complex survey design.

Results

  • The study population had a mean baseline age of 39.0 years (95% CI, 38.4–39.5), with 50.9% being female.

  • Over a median follow-up period of 5.8 years (range: 0.8–9.6 years), 1,262 new diabetes cases were recorded.

  • The analysis revealed that greater energy intake and GL during the late morning (9:00–11:59 a.m.) were associated with a lower risk of developing diabetes.

  • The HR for diabetes was 0.94 (95% CI, 0.91–0.97) per 100-kcal increase in energy intake and 0.93 (95% CI, 0.89–0.97) per 10-unit increase in GL during the late morning.

  • Higher energy intake and GL at other times of the day did not show a significant association with diabetes risk.

This study identified a relationship between meal timing and diabetes risk in Hispanic/Latino adults. A higher intake of late-morning calories and greater late-morning glycemic load is inversely associated with incident T2D. The association remained significant after adjustment for multiple variables: diet quantity and quality, sociodemographic characteristics, lifestyle factors, and chronic conditions.

It also demonstrated that when something was eaten was equally as important as what was eaten. Replacing energy intake or GL from other times of the day with late-morning equivalents showed a comparably reduced risk of diabetes. It may indicate that late-morning meals probably have additional advantages in strategies to prevent diabetes.

The HCHS/SOL study identified late morning as a favorable time for meals to reduce the risk of type 2 diabetes in Hispanic/Latino adults. This is a new concept for meal timing in the prevention of diabetes that needs further confirmation in future studies. This dietary pattern—characterized by higher late-morning intake of energy and GL—may be one simple but ideal approach to reducing the risk of diabetes in such a population.

Reference:

Dai, J., Nianogo, R., Wong, N. D., Moin, T., McClain, A. C., Alver, S., Cordero, C., Daviglus, M. L., Qi, Q., Sotres-Alvarez, D., & Chen, L. (2024). Energy intake and dietary glycemic load in late morning and risk of type 2 diabetes: The Hispanic Community Health Study/study of Latinos, a multicenter prospective cohort study. Diabetes Care, dc240564. https://doi.org/10.2337/dc24-0564

Powered by WPeMatico

Grape Syrup Shows Potential for Enhancing Hematological Parameters in Iron Deficiency Anemia: Study

Researchers have found a treatment for iron deficiency anemia in which grape syrup normalizes some of the key blood parameters when used with standard iron supplementation. The findings were recently published in the Food Science Nutrition journal by Pourhakim R. and colleagues. Randomized clinical trial in hemoglobin (Hb), hematocrit, red blood cell count (RBC), and mean corpuscular volume (MCV) laboratory parameters were found to have significant improvement in the group that received grape syrup with the ferrous sulfate tablets compared with placebo, underscoring that grape syrup is a useful adjunctive therapeutic modality. The results of the trial would therefore underline that it will bring an incremental advantage for patients with this very common nutritional disorder.

Iron-deficiency anemia is the most prevalent nutritional deficiency disorder in the world. It primarily occurs in females of childbearing age, pregnant females, and the elderly. The World Health Organization recognizes that iron deficiency anemia is a significant public health concern based on the economic burden of its impact, coupled with frailty-linked comorbidities. Conventional iron supplements are effective, although their usage is often limited by gastrointestinal side effects. In search of more tolerable complementary therapies, a team led by Fatemeh Emadi from the Traditional Medicine Clinical Trial Research Center, Shahed University, probed into a possible role of grape syrup in improving hematological markers among women with iron deficiency anemia.

This was a randomized, double-blind clinical trial carried out from February 2020 to October 2022 with 130 women in the age group of 15 to 49 years diagnosed to have anemia. The participants were randomized into two groups: an intervention group, which received locally procured grape syrup and daily 50 mg ferrous sulfate, and another placebo group, which received placebo syrup with the same iron supplementation. After accounting for the dropouts, 80 participants had completed the study, 40 in each group.

The primary outcome measured was the change in hemoglobin levels over a period of 4 weeks. Secondary outcomes included changes in other laboratory markers such as RBC count or MCV, adverse effects, dropout rates, and quality of life assessments. The patients in the intervention group were asked to take 10 cc of grape syrup three times daily, 1 hour before lunch and dinner. The placebo group followed the same schedule but with the placebo syrup.

Key Findings

  • After 4 weeks, both groups showed significant improvements in hematological markers.

However, the grape syrup group demonstrated markedly greater increases:

  • RBC count significantly increased in the grape syrup group compared to placebo (P = .003).

  • MCV levels also saw a more substantial rise in the grape syrup group (P = .002).

  • Hemoglobin (Hb) and hematocrit levels increased significantly more in the grape syrup group compared to placebo (P = .0001).

  • Despite the marked improvement in other hematological markers, there were no significant differences between the grape syrup and placebo groups in serum iron, ferritin, or total iron-binding capacity (TIBC) levels (P >.05).

  • Although overall quality of life scores did not differ significantly between the two groups, the grape syrup group showed a statistically significant improvement in these scores. Both groups reported mild gastrointestinal side effects, including nausea and stomach discomfort, with a slightly higher incidence in the placebo group.

This study provides evidence that grape syrup has beneficial effects as a complementary therapy in the management of iron deficiency anemia. These additional benefits to the standard iron supplementation in elevating key hematological parameters, especially hemoglobin and hematocrit levels, are therefore indicative that grape syrup could be an effective adjunct. It may be assumed that this by-product has a greater effect on the bioavailability of iron from standard supplementation rather than on the direct level of iron itself, as was indicated by the fact that serum iron and ferritin were not significantly changed by the consumption of grape syrup infused with iron.

The randomized clinical trial proved that grape syrup supplementation, plus iron, significantly improved the hematological markers of hemoglobin, hematocrit, RBC count, and MCV in women with iron deficiency anemia. While the syrup had no remarkable effects on either the serum iron or ferritin levels, complementary effects are to some extent promising alternatives that may help improve traditional anemia treatment. Further studies should be conducted to confirm the results and determine the long-term benefits.

Reference:

Pourhakim R, Emadi F, Razavi Dizaji S, Talei D, Esmaeili Saber SS, Iranzadasl M. Evaluating the effect of grape syrup on iron deficiency anemia in women: A randomized clinical trial. Food Sci Nutr. 2024;12(8):5473-5479. Published 2024 May 6. doi:10.1002/fsn3.4185

Powered by WPeMatico

CRP to albumin ratio indicates disease activity in juvenile idiopathic arthritis patients: Study

A new study by Giulia Di Donato and team found that in individuals with juvenile idiopathic arthritis (JIA), the neutrophil to lymphocyte ratio (NLR) and the C reactive protein to albumin ratio (CAR) may provide evidence of ongoing disease activity. The findings of this study were published in the journal of BMC Rheumatology.

The most common chronic rheumatic condition in children, JIA is a major contributor to both short- and long-term impairment as well as a lower quality of life. The last 20 years have seen the introduction of combination therapy plans and targeted medicines due to increased understanding of JIA etiology. New derivative indicators have emerged as promising biomarkers of systemic inflammation and disease activity in individuals with autoimmune disorders, including rheumatoid arthritis (RA), according to recent scientific research.

Studies on adult RA patients has demonstrated a favorable relationship between disease activity, likelihood of flare, and CRP to CAR. Additionally, number of studies have raised the possibility that NLR and the platelet to lymphocyte ratio (PLR) may serve as supplementary diagnostic tools and inflammatory indicators in RA and other rheumatic disorders. The primary goal of this study was to look at the function of CAR, PLR, and NLR as possible disease activity markers in patients with non-systemic JIA (nsJIA). The second goal was to longitudinally explore the link between CAR, PLR, and NLR with the probability of flare or chronic disease activity over an 18-month period.

A total of 130 nsJIA patients, with 74 patients undergoing active disease and 56 patients undergoing inactive disease, based on Wallace criteria and 62 healthy controls participated in this prospective, cross-sectional study. During follow-up, demographic, clinical, and laboratory data were gathered at baseline (T0), as well as at three, six, twelve, and eighteen months (T1, T2, and T4). The Juvenile Arthritis Disease Activity Score was used to assess disease activity (JADAS-27).

At baseline, there were no differences in NLR or PLR, although CRP and CAR were greater in patients than in controls. But, among the JIA patients, there was no positive link found between CAR, NLR, PLR, and JADAS-27. A generalized estimating equation (GEE) model was implemented to all patients with or without active illness, to better evaluate the function of CAR, NLR, and PLR as indicators of disease activity. This study showed that baseline CAR and NLR levels were indicative of increased disease activity risk at 6-month follow-up (p<0.001). Overall, CAR to NLR value might be strengthened by their combined usage and the study of their trend during follow-up, since increasing CAR levels over time could indicate a disease flare in a short period.

Reference:

Di Donato, G., Attanasi, M., Mariarita d’ Angelo, D., La Bella, S., Di Ludovico, A., Chiarelli, F., & Breda, L. (2024). Associations of C reactive protein to albumin ratio, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio with disease activity in patients with juvenile idiopathic arthritis. In BMC Rheumatology (Vol. 8, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1186/s41927-024-00390-x

Powered by WPeMatico